You are here

  • Home
  • Archive
  • Volume 83, Issue 4
  • Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

Article info

Article menu
Systemic lupus erythematosus
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial

Authors

  • Di Wu Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Jing Li Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Dong Xu Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  • Joan T Merrill University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma, USA PubMed articlesGoogle scholar articles
  • Ronald F van Vollenhoven Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands PubMed articlesGoogle scholar articles
  • Yi Liu Department of Rheumatology and Immunology, West China Hospital of Sichuan University, Chengdu, Sichuan, China PubMed articlesGoogle scholar articles
  • Jiankang Hu Department of Rheumatology and Immunology, Jiangxi Pingxiang People’s Hospital, Pingxiang, Jiangxi, China PubMed articlesGoogle scholar articles
  • Yang Li Department of Rheumatology and Immunology, Guangdong People's Hospital, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Fen Li Department of Rheumatology and Immunology, Second Xiangya Hospital of Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Chenghui Huang Department of Rheumatology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Guochun Wang Department of Rheumatology and Immunology, China-Japan Friendship Hospital, Beijing, China PubMed articlesGoogle scholar articles
  • Xiaomei Li Department of Rheumatology and Immunology, Anhui Provincial Hospital, Hefei, Anhui, China PubMed articlesGoogle scholar articles
  • Jianhong Zhao Department of Rheumatology and Immunology, Jining No. 1 People's Hospital, Jining, Shandong, China PubMed articlesGoogle scholar articles
  • Dongbao Zhao Department of Rheumatology and Immunology, Changhai Hospital, Shanghai, China PubMed articlesGoogle scholar articles
  • Cibo Huang Department of Rheumatology and Immunology, South China Hospital of Shenzhen University, Shenzhen, Guangdong, China PubMed articlesGoogle scholar articles
  • Huaxiang Liu Department of Rheumatology, Qilu Hospital of Shandong University, Jinan, Shandong, China PubMed articlesGoogle scholar articles
  • Wei Wei Department of Rheumatology and Immunology, Tianjin Medical University General Hospital, Tianjin, China PubMed articlesGoogle scholar articles
  • Guixiu Shi Department of Rheumatology and Immunology, The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China PubMed articlesGoogle scholar articles
  • Fuai Lu Department of Rheumatology and Immunology, The First Affiliated Hospital of Baotou Medical College, Inner Mongolia University of Science and Technology, Baotou, Inner Mongolia, China PubMed articlesGoogle scholar articles
  • Xiaoxia Zuo Department of Rheumatology and Immunology, Xiangya Hospital, Central South University, Changsha, Hunan, China PubMed articlesGoogle scholar articles
  • Liqi Bi Department of Rheumatology and Immunology, China-Japan Union Hospital of Jilin University, Changchun, Jilin, China PubMed articlesGoogle scholar articles
  • Zhijun Li Department of Rheumatology and Immunology, The First Affiliated Hospital of Bengbu Medical College, Bengbu, Anhui, China PubMed articlesGoogle scholar articles
  • Xiaoxia Wang Department of Rheumatology and Immunology, Second Hospital of Shanxi Medical University, Taiyuan, Shanxi, China PubMed articlesGoogle scholar articles
  • Miaojia Zhang Department of Rheumatology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China PubMed articlesGoogle scholar articles
  • Ning Tie Department of Rheumatology and Immunology, The Affiliated Hospital of Inner Mongolia Medical University, Hohhot, Inner Mongolia, China PubMed articlesGoogle scholar articles
  • Juan Li Rheumatology of Traditional Chinese Medicine, Nanfang Hospital, Guangzhou, Guangdong, China PubMed articlesGoogle scholar articles
  • Hanyou Mo Department of Rheumatology and Immunology, The First Affiliated Hospital of Guangxi Medical University, Nanning, Guangxi, China PubMed articlesGoogle scholar articles
  • Jianmin Fang School of Life Science and Technology, Tongji University, Shanghai, China RemeGen Co., Ltd, Yantai, Shandong, China PubMed articlesGoogle scholar articles
  • Chunde Bao Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China PubMed articlesGoogle scholar articles
  • Fengchun Zhang Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, Beijing, China PubMed articlesGoogle scholar articles
  1. Correspondence to Professor Fengchun Zhang, Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College; National Clinical Research Center for Dermatologic and Immunologic Diseases (NCRC-DID), Ministry of Science & Technology; State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical College Hospital (PUMCH); Key Laboratory of Rheumatology and Clinical Immunology, Ministry of Education, No.1 Shuaifuyuan, Dongcheng district 100730, Beijing, China; zhangfccra{at}aliyun.com; Professor Chunde Bao; baochunde_1678{at}126.com; Dr Jianmin Fang; jfang{at}tongji.edu.cn
View Full Text

Citation

Wu D, Li J, Xu D, et al
Telitacicept in patients with active systemic lupus erythematosus: results of a phase 2b, randomised, double-blind, placebo-controlled trial
Annals of the Rheumatic Diseases 2024;83:475-487.

Publication history

  • Received August 15, 2023
  • Accepted November 3, 2023
  • First published December 21, 2023.
Online issue publication 
March 12, 2024

Article Versions

  • Supplementary Data

    This web only file has been produced by the BMJ Publishing Group from an electronic file supplied by the author(s) and has not been edited for content.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Copyright information

© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. http://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.